Literature DB >> 2570799

Differential cognitive effects of terfenadine and chlorpheniramine.

K J Meador1, D W Loring, E E Thompson, W O Thompson.   

Abstract

The H1-histamine antagonist, terfenadine, has been proposed to have reduced cognitive side effects. In the present study, the relative cognitive effects of terfenadine, 60 mg, chlorpheniramine maleate, 8 mg, and placebo were tested with a double-blind, randomized, three-period crossover design in 24 healthy adult subjects. The dependent variable was latency of the P3-evoked potential. The P3 is a cognitively evoked electroencephalographic response that is an objective and sensitive measure of sustained attention and cerebral processing speed. Disease and drug states that adversely affect the central nervous system can slow P3 latency. For example, the centrally active anticholinergic scopolamine slows cognitive processing speed and prolongs P3 latency. P3 latency (millisecond) means (+/- mean standard error) were pretreatment, 310 (+/- 1.7; placebo, 313 (+/- 3); terfenadine, 320 (+/- 3); and chlorpheniramine, 333 (+/- 3). The findings suggest that terfenadine may be particularly advantageous in patients who require alertness and intact cognitive abilities.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570799     DOI: 10.1016/0091-6749(89)90415-6

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

Review 1.  Brain histamine modulates recognition memory: possible implications in major cognitive disorders.

Authors:  Gustavo Provensi; Alessia Costa; Ivan Izquierdo; Patrizio Blandina; Maria Beatrice Passani
Journal:  Br J Pharmacol       Date:  2018-09-22       Impact factor: 8.739

Review 2.  Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

3.  Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine.

Authors:  N Okamura; K Yanai; M Higuchi; J Sakai; R Iwata; T Ido; H Sasaki; T Watanabe; M Itoh
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

4.  Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration.

Authors:  Masaaki Tagawa; Michiko Kano; Nobuyuki Okamura; Makoto Higuchi; Michiaki Matsuda; Yasuyuki Mizuki; Hiroyuki Arai; Toshihiko Fujii; Sadao Komemushi; Masatoshi Itoh; Hidetada Sasaki; Takehiko Watanabe; Kazuhiko Yanai
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 5.  Effects of antihistamine medications on exercise performance. Implications for sportspeople.

Authors:  L C Montgomery; P A Deuster
Journal:  Sports Med       Date:  1993-03       Impact factor: 11.136

6.  Histamine H1 receptor blockade predominantly impairs sensory processes in human sensorimotor performance.

Authors:  P van Ruitenbeek; A Vermeeren; F T Y Smulders; A Sambeth; W J Riedel
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

Review 7.  H1-receptor antagonists. Comparative tolerability and safety.

Authors:  F E Simons
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.